Tag: Medtronic

Medtronic Announces First Procedures in Pivotal Trial to Evaluate Novel Ablation Technology in Treating Atrial Fibrillation

Study Will Determine the Safety and Effectiveness of Pulsed Electrical Fields to Interrupt Irregular Heart Rhythms DUBLIN, March 4, 2021 /PRNewswire/ — Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the first procedures in the investigational device exemption (IDE) pivotal trial to evaluate the PulseSelect™ Pulsed Field Ablation (PFA) System, a […]

New Analysis of REVERSE Trial Reveals Benefits of CRT for More Patients with Heart Failure

JACC: Clinical Electrophysiology: Findings Highlight Need to Better Classify Heart Failure Outcomes DUBLIN, March 2, 2021 /PRNewswire/ — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced new results from the landmark REVERSE trial, evaluating outcomes of cardiac resynchronization therapy (CRT) for patients with mild heart failure (HF). This new […]

Medtronic Reports Third Quarter Fiscal 2021 Financial Results

– Q3 Revenue of $7.8 Billion Increased 0.8% as Reported and Decreased 1.0% Organically –  Q3 GAAP Diluted EPS of $0.94; Q3 Non-GAAP Diluted EPS of $1.29 DUBLIN, Feb. 23, 2021 /PRNewswire(opens new window)/ — Medtronic plc (NYSE:MDT) today announced financial results for its third quarter of fiscal year 2021, which ended January 29, 2021. The company reported […]

Medtronic Announces Voluntary Recall of Unused Valiant Navion™ Thoracic Stent Graft System

DUBLIN, Feb. 17, 2021 /PRNewswire/ — Medtronic plc (NYSE:MDT), the global leader in medical technology, has voluntarily issued a global recall of unused Medtronic Valiant Navion™ thoracic stent graft system and informed physicians to immediately cease use of the device until further notice. In accordance with its commitment to patient safety – […]

Medtronic Announces Early Site Release of New Radial Artery Access Portfolio Following First-in-Patient Procedure

Acquisition of RIST Neurovascular Enhances Medtronic’s Capabilities to Serve Patients Treated for Brain Aneurysms and Other Neurovascular Conditions DUBLIN, Feb. 1, 2021 /PRNewswire/ — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced expansion of its limited site release of the recently acquired radial artery access portfolio from privately-held RIST Neurovascular, […]

Medtronic Receives FDA Approval of DiamondTemp Ablation System for the Treatment of Patients with Atrial Fibrillation

Clinical Trial Demonstrates Procedural Efficiencies, Safety, Effectiveness and Non-Inferiority of DiamondTemp System DUBLIN, Jan. 29, 2021 /PRNewswire/ — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval of the DiamondTemp™ Ablation (DTA) system which treats patients with recurrent, symptomatic paroxysmal atrial […]

Sean Salmon Named EVP & President Cardiovascular Portfolio; Continues as EVP & President Diabetes Operating Unit

DUBLIN, Dec. 14, 2020 /PRNewswire/ — Medtronic plc (NYSE:MDT) announced today that Sean Salmon, Executive Vice President and President, Diabetes Operating Unit has been named Executive Vice President and President, Cardiovascular Portfolio effective January 1. Salmon will also continue to lead the Diabetes Operating Unit and continue to serve on the company’s Executive Committee. He […]

Medtronic Reports Second Quarter Fiscal 2021 Financial Results

– Q2 Revenue of $7.6 Billion Decreased 0.8% Reported and 1.5% Organic – Q2 GAAP Diluted EPS of $0.36; Q2 Non-GAAP Diluted EPS of $1.02 DUBLIN, Nov. 24, 2020 /PRNewswire/ — Medtronic plc (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2021, which ended October 30, 2020. The company reported second quarter worldwide revenue of $7.647 billion, […]

The New England Journal of Medicine: Medtronic Cryoablation is a Superior Treatment Option for Symptomatic Paroxysmal Atrial Fibrillation Compared to Drug Therapy

Results from Three Studies Show Medtronic Cryoablation is Superior to Drug Therapy for First-Line Treatment DUBLIN, Nov. 16, 2020 /PRNewswire(opens new window)/ — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that the primary results of the Medtronic-sponsored STOP AF First clinical trial have been published in the New England […]

Medtronic Venous Stent Receives U.S. FDA Approval to Treat Venous Outflow Obstruction

Abre™ Venous Self-Expanding Stent System Safe, Effective in Treating Challenging Deep Venous Lesions DUBLIN, Oct. 26, 2020 /PRNewswire(opens new window)/ — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval for the Abre™ venous self-expanding stent system. This device is indicated for […]